Bismuth subcitrate potassium

Bismuth Subcitrate Potassium Overview

Bismuth subcitrate potassium (often supplied as bismuth subcitrate potassium monohydrate) is a complex bismuth and potassium salt of citric acid. Chemically, it belongs to the class of organic compounds known as tricarboxylic acids and derivatives within the organic acids and derivatives superclass. Structurally, it consists of a colloidal bismuth complex stabilized with citrate carboxylate groups and potassium counter-ions.

In gastroenterology and clinical anti-infective pharmacology, Bismuth subcitrate potassium is classified as a mucosal protective agent, anti-ulcer agent, and bismuth-containing anti-infective (ATC code A02BX). It is primarily indicated as an essential component of quadruple therapy regimens in combination with metronidazole, tetracycline, and a proton pump inhibitor (PPI) for the eradication of Helicobacter pylori (H. pylori) infection in adult patients with active or historical peptic ulcer disease. Marketed under the brand name Pylera, Bismuth subcitrate potassium exerts direct antibacterial actions against H. pylori while coating and protecting mucosal lesions, accelerating the healing of gastritis, duodenitis, and peptic ulcers.

What Is Bismuth Subcitrate Potassium and How Does It Work?

Bismuth subcitrate potassium is a colloidal bismuth derivative that acts through a combination of bactericidal activity against H. pylori and gastric mucosal cytoprotection.

Its primary physiological, biochemical, and antimicrobial mechanisms include:

• Direct Bactericidal Action Against H. Pylori: Bismuth subcitrate potassium disrupts H. pylori cell walls, inhibits bacterial ATP-dependent Clp protease (ClpX), and blocks essential bacterial enzymes, including proteases, lipases, glycosidases, and phospholipases. It also prevents bacterial adhesion to gastric epithelial cells.
• Gastric Mucosal Protective Barrier: In the acidic environment of the stomach, colloidal bismuth precipitates out and selectively binds to proteinaceous exudates within ulcer bases, forming a physical diffusion barrier against gastric acid (HCl) and pepsin.
• Endogenous Cytoprotection: It stimulates mucosal production and secretion of endogenous prostaglandins (PGE2​), mucus glycoproteins, and bicarbonate ions (HCO3−​), promoting mucosal repair and accumulating epidermal growth factor (EGF) around ulcer sites.
• Inhibition of Pepsin Activity: While it does not alter basal gastric acid secretion or raise intragastric pH directly, it complexes with pepsin, inhibiting peptic digestion of vulnerable mucosal tissue.

Is Bismuth Subcitrate Potassium FDA Approved?

Yes, Bismuth Subcitrate Potassium is approved by the US FDA. It received its official New Drug Application approval on September 28, 2006 under the trade name Pylera (manufactured by AbbVie / Allergan) as a 3-in-1 fixed-dose combination capsule (containing 140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride). Co-administered alongside a proton pump inhibitor, it serves as an established first-line quadruple therapy regimen for the eradication of Helicobacter pylori in the United States.

What Is Bismuth Subcitrate Potassium Used For?

• Eradication of Helicobacter pylori in adult patients with H. pylori infection and duodenal or gastric ulcer disease (administered alongside a proton pump inhibitor).
• Treatment of inflammatory and erosive-ulcerative mucosal disorders, including chronic gastritis, gastric/duodenal ulcers, and erosive duodenitis.
• Symptomatic management of gastro-esophageal reflux disease (GERD) and functional non-ulcer dyspepsia (in select international jurisdictions).

Before Taking Bismuth Subcitrate Potassium: Contraindications & Precautions

Strictly contraindicated in severe renal impairment (CrCl < 30 mL/min) or ESRD due to bismuth toxicity risks. Do not use during pregnancy or lactation due to fetal bone/dental hazards from co-formulated tetracycline and metronidazole risks. Avoid in severe hepatic impairment or known component hypersensitivity.

Who Should Not Take Bismuth Subcitrate Potassium?

• Patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease, as bismuth clearance is severely compromised, raising the risk of systemic bismuth toxicity.
• Patients taking Pylera who have severe hepatic impairment.
• Pregnant or breastfeeding women (owing to tetracycline-induced bone/dental fetal toxicity and metronidazole risks in Pylera).
• Individuals with a documented hypersensitivity to bismuth subcitrate potassium, metronidazole, tetracycline, or citrate formulation components.

Bismuth Subcitrate Potassium, Pregnancy & Fertility

Bismuth subcitrate potassium as part of combination regimens like Pylera is contraindicated during pregnancy. Tetracycline causes permanent tooth discoloration and enamel hypoplasia in the fetus, while metronidazole poses potential mutagenic and fetotoxic risks. Nursing mothers should avoid bismuth combination therapy or suspend breastfeeding during treatment.

Tell Your Doctor Before Taking Bismuth Subcitrate Potassium

Inform your gastroenterologist if you have a history of kidney disease, liver disease, central nervous system disorders, or blood dyscrasias. Disclose all concurrent medications, especially anticoagulants, oral contraceptives, or antacids.

Bismuth Subcitrate Potassium Dosage & Administration

Formulated in combination capsules (Pylera: 140 mg bismuth subcitrate potassium, 125 mg metronidazole, 125 mg tetracycline). Standard adult dosing is 3 capsules taken orally 4 times daily (after main meals and at bedtime) for 10 days, co-administered with a PPI twice daily. Swallow whole with 8 ounces of water.

Standard Bismuth Subcitrate Potassium Dosing

• Pylera Combination Regimen (H. Pylori Eradication): The standard adult dosage is 3 Pylera capsules (each containing 140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline) taken orally 4 times daily (after meals and at bedtime) for 10 consecutive days.
• A proton pump inhibitor (e.g., omeprazole 20 mg) must be co-administered orally twice daily with the morning and evening Pylera doses.

How Bismuth Subcitrate Potassium Is Administered

• Administered strictly via the oral route in capsule or tablet form.
• Swallow capsules whole with a full glass of water (8 ounces) after main meals and at bedtime to minimize esophageal irritation and gastrointestinal distress.
• Maintain an upright posture for at least 30 minutes after taking bedtime doses.

Bismuth Subcitrate Potassium Clinical Efficacy & Research

Clinical trials confirm that 10-day bismuth-based quadruple therapy achieves H. pylori eradication rates exceeding 85% to 90%. Incorporating colloidal bismuth overcomes bacterial resistance to clarithromycin or metronidazole and enhances antibiotic penetration through the gastric mucus layer.

Bismuth Subcitrate Potassium Side Effects & Safety Profile

Common side effects include harmless black discoloration of stools and tongue, nausea, diarrhea, metallic taste, and headache. Serious risks include bismuth neurotoxicity/encephalopathy (confusion, tremors, ataxia) in renal impairment, C. difficile colitis, and severe cutaneous reactions. Holds no standalone FDA Black Box Warning.

Common Bismuth Side Effects

• Black or dark discoloration of stools and darkening of the tongue.
• Gastrointestinal distress: Nausea, diarrhea, abdominal pain, metallic taste, and dyspepsia.
• Central nervous system effects: Mild headache or dizziness.

Serious Bismuth Adverse Events

• Bismuth Neurotoxicity & Encephalopathy: High systemic bismuth absorption (particularly in patients with renal impairment) can lead to confusion, tremors, myoclonus, ataxia, and severe encephalopathy.
• Pseudomembranous Colitis: Clostridioides difficile-associated diarrhea secondary to broad-spectrum antibiotic therapy.
• Severe Cutaneous Hypersensitivity: Rare cases of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Managing Bismuth Side Effects

Darkening of the stool and tongue is a benign, temporary result of bismuth interacting with trace sulfur in the gastrointestinal tract, which resolves after completing therapy. If severe neurological symptoms (confusion, tremors) or profuse watery diarrhea develop, discontinue therapy and seek immediate medical evaluation.

Bismuth Subcitrate Potassium Drug Interactions & What to Avoid

Alcohol induces a severe disulfiram-like reaction with metronidazole; avoid during and for 3 days after therapy. Multivalent cations (calcium, iron, magnesium) and antacids chelate tetracycline, reducing absorption. Potentiates warfarin anticoagulant effects. Avoid concurrent high-calcium dairy intake.

Bismuth Subcitrate Potassium Drug-Drug Interactions

• Oral Anticoagulants (e.g., Warfarin): Bismuth combination therapy alters gut microflora and clearance, potentiating hypoprothrombinemic effects and increasing bleeding risks.
• Multivalent Cations & Antacids (e.g., Calcium, Iron, Magnesium): Direct chelation with tetracycline in combination pills reduces antibiotic bioavailability; avoid co-administering multivitamin or antacid products.
• Alcohol & Ethanol-Containing Products: Metronidazole within Pylera produces a severe disulfiram-like reaction (flushing, severe nausea, vomiting, tachycardia) if combined with alcohol.

Bismuth Subcitrate Potassium, Food & Alcohol

Avoid all alcohol consumption during Pylera treatment and for at least 3 days after completing the 10-day course. Take capsules after meals with plenty of water. Avoid taking concurrently with dairy products high in calcium, which can bind tetracycline.

Bismuth Subcitrate Potassium: Missed Dose, Overdose & Storage

If a dose is missed, take the 3 capsules with food as soon as remembered on that day; do not double doses. Acute overdose causes severe GI irritation, acute renal failure, and encephalopathy, requiring emergency fluid rehydration, hemodialysis, or chelation. Store capsules between 20°C and 25°C (68°F–77°F).

Missed Dose of Bismuth Subcitrate Potassium

If a dose of Pylera is missed, take the missed 3 capsules as soon as remembered on that day with food. Continue the 10-day course until all capsules are finished. Do not double up on doses. If more than 4 doses are missed, contact your physician for guidance.

Bismuth Subcitrate Potassium Overdose & Emergency

Acute overdose causes severe gastrointestinal irritation, acute renal failure, and bismuth encephalopathy. Seek immediate emergency medical care for gastric lavage, fluid rehydration, hemodialysis, or chelation therapy (e.g., dimercaprol) if severe bismuth accumulation occurs.

How to Store Bismuth Subcitrate Potassium

Store Pylera capsules at controlled room temperature between 20°C and 25°C (68°F to 77°F). Protect from excessive heat and moisture. Keep strictly out of reach of children.

Bismuth Subcitrate Potassium Patient Management & Monitoring

Confirm active H. pylori infection and assess baseline renal/hepatic panels prior to treatment initiation. Educate patients that dark stools are expected. Confirm bacterial eradication using a urea breath test or stool antigen test at least 4 weeks after completing therapy and stopping PPIs.

Tests Before Starting Bismuth Subcitrate Potassium

• Diagnostic confirmation of active H. pylori infection (e.g., urea breath test, stool antigen test, or endoscopy biopsy).
• Baseline renal function panel (serum creatinine, eGFR) and hepatic function panel.

Monitoring During Bismuth Subcitrate Potassium Treatment

Re-evaluate H. pylori eradication using a urea breath test or stool antigen test at least 4 weeks after completing the 10-day course and stopping PPI therapy.

Bismuth Subcitrate Potassium Do’s and Don’ts

• Do take all 3 capsules 4 times daily with meals and a full glass of water.
• Do expect stools and tongue to turn dark or black during treatment.
• Do not consume alcohol during or for 3 days after treatment.
• Do not take dairy or iron supplements at the same time as Pylera.

Frequently Asked Questions

References

• DrugBank Database – Bismuth Subcitrate Potassium Clinical Profile (DB09275)
• Official FDA Prescribing Information – Pylera (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) Capsules

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.